Arturo Tamayo

TL;DR: Cardiovascular events and microemboli on TCD have markedly declined with more intensive medical therapy and less than 5% of patients with ACS now stand to benefit from revascularization.

TL;DR: 3D plaque volume measurement can show large effects of therapy on atherosclerosis in 3 months in sample sizes of ≈20 patients per group, which would be sufficient to show an effect size of 25% that of atorvastatin in 6 months.

TL;DR: The findings indicate that TCD− ACS will not benefit from endarterectomy or stenting unless it can be done with a risk <1%; TCD+ may benefit as much as SCS if their surgical risk is not higher.

TL;DR: The 2017 update of The Canadian Stroke Best Practice Recommendations for the Secondary Prevention of Stroke is a collection of current evidence-based recommendations intended for use by clinicians across a wide range of settings to provide guidance for the prevention of ischemic stroke recurrence through the identification and management of modifiable vascular risk factors.

TL;DR: Until 3-year event rates of stroke or death with endarterectomy or stenting reach <2%, 90% of patients with ACS would be better treated medically until they develop symptoms, ulcers, or emboli.